Rose McNulty

Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, discussed the issue of cost and optimizing patient outcomes acute myeloid leukemia (AML).

The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.

Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

Craig D. Pederson, principal at Insight Health Care Partners, discussed the evolving landscape of value-based care and challenges to implementation from the provider perspective during his keynote presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

A session led by Irina Koyfman, DNP, NP-C, RN, at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 detailed the potential of chronic care management billing for physicians who are not currently doing it and recommendations for optimizing the process.

Todd A. Zigrang, MBA, MHA, FACHE, CVA, ASA, ABV, president of Health Capital Consultants, discusses accountable care organizations (ACOs) and the move toward value-based care models.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, discusses the importance of biomarker testing in non–small cell lung cancer (NSCLC).

In a presentation at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023, Robert L. Waterhouse Jr, MD, MBA, HSM, chief medical officer at Baylor Scott & White Quality Alliance, discussed the challenges of value-based care implementation and how to overcome them.

Some of the health care transformations that were forced by the COVID-19 pandemic could continue to benefit patients and the health care system, Jacques Sokolov, MD, said during his keynote address at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).

Eric Lisle, president and CEO of Southeast Primary Care Partners, discusses the importance of comprehensive patient data for primary care practices implementing value-based care.

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

The National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023 will highlight topics in value-based care from a business standpoint and managed care decision-making across a host of disease settings on April 27-28 in Orlando, Florida.

Jacque Sokolov, MD, president and chairman at SSB Solutions, previews his keynote presentation and discusses the unique, shifting health care atmosphere leading into the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum 2023.

A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

Adding motixafortide to standard stem cell mobilization therapy for autologous hematopoietic stem cell transplantation (ASCT) significantly improved collection success rates vs standard therapy plus a placebo in a phase 3 trial of patients with multiple myeloma.

Coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit.

The review aimed to characterize the impacts of clinical response, delayed disease progression, and lines of therapy on health-related quality of life (HRQOL) for patients with multiple myeloma.

A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.

Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

A secondary analysis of the phase 3 TOURMALINE-MM4 trial found that ixazomib as postinduction maintenance therapy for multiple myeloma produced a progression-free survival (PFS) benefit vs a placebo across age and frailty subgroups.